ArticleInternational journal of environmental research and public health2022
The Effect of Transborder Mobility on COVID-19 Incidences in Belgium.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Impact of Public Health and Social Measures (PHSMs) on SARS-CoV-2 Transmission in the WHO European Region (2020-2022).Influenza and other respiratory viruses · 2024Article
- Cross-border mobility in the Meuse-Rhine Euroregion: impact of COVID-19 border restrictions on everyday activities and visiting social network members.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Belgium is a geographically small country bordered by The Netherlands, France, Germany, and Luxembourg, with intense transborder mobility, defined as mobility in the border regions with neighboring countries. It is therefore of interest to examine how the 14-day COVID-19 confirmed case incidence in the border regions is influenced by that of the adjacent regions in the neighboring countries and thus, whether and how it differs from that in the adjacent non-border regions within Belgium. To this end, the 14-day COVID-19 confirmed case incidence is studied at the level of Belgian provinces, well-defined border areas within Belgium, and adjacent regions in the neighboring countries. Auxiliary information encompasses work-related border traffic, travel rates, the proportion of people with a different nationality, the stringency index of the non-pharmaceutical interventions, and the degree of urbanization at the level of the municipality. Especially in transnational urbanized areas such as between the Belgian and Dutch provinces of Limburg and between the Belgian province of Antwerp and the Dutch province of North Brabant, the impact on incidence is visible, at least at some points in time, especially when the national incidences differ between neighboring countries. In contrast, the intra-Belgian language border regions show very little transborder impact on the incidence curves, except around the Brussels capital region, leading to various periods where the incidences are very different in the Dutch-speaking north and the French-speaking south of Belgium. Our findings suggest that while travel restrictions may be needed at some points during a pandemic, a more fine-grained approach than merely closing national borders may be considered. At the same time, in border regions with considerable transborder mobility, it is recommended to coordinate the non-pharmaceutical interventions between the authorities of the various countries overlapping with the border region. While this seems logical, there are clear counterexamples, e.g., where non-essential shops, restaurants, and bars are closed in one country but not in the neighboring country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.